Physician profile
Rohit Jain
NPI 1548594344
$2,139.94
in general payments reported to CMS, 2019-2025
22 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2022: $52.57 · 2023: $942 · 2024: $791 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,915 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,915.11 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $348.45 | 2023-2024 | |
| Dexcom, INC. | $280.82 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $231.93 | 2022-2024 | Jardiance, Mounjaro |
| Novo Nordisk INC | $200.25 | 2019-2025 | Wegovy |
| Beta Bionics, INC. | $177.83 | 2023-2024 | Ilet Bionic Pancreas |
| Aveo Pharmaceuticals, INC. | $144.14 | 2023 | Fotivda |
| Insulet Corporation | $136.43 | 2024-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $129.65 | 2023 | |
| Tandem Diabetes Care, INC. | $79.92 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| E.R. Squibb & Sons, L.L.C. | $79.36 | 2023 | |
| Abbott Laboratories | $48.74 | 2023-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $42.64 | 2023 | Recorlev |
| Mannkind Corporation | $42.50 | 2025 | |
| Amgen INC. | $37.24 | 2024 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.18 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $23.06 | 2024 | Signifor Lar, Isturisa |
| Ascendis Pharma Endocrinology INC | $22.77 | 2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $20.02 | 2024 | Gardasil 9, Gardasil |
| Astrazeneca Pharmaceuticals LP | $19.82 | 2023 | Saphnelo |
| Antares Pharma, INC. | $17.41 | 2023 | Nocdurna, Tlando, Xyosted |
| Astellas Pharma US INC | $16.09 | 2024 | Veozah |
| Halozyme INC | $15.69 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.